Ameriprise
XGN icon

Ameriprise’s Exagen XGN Stock Holding History

Ameriprise’s Portfolio XGN Stock Details XGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-192,419
Closed -$1.17M – 4232
2025
Q4 		$1.17M Buy
192,419
+64,071
+50% +$583K ﹤0.01% 3257
2025
Q3 		$1.41M Buy
128,348
+33,395
+35% +$296K ﹤0.01% 3191
2025
Q2 		$663K Buy
+94,953
New +$577K ﹤0.01% 3427

Other funds holding XGN

Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
WC
Wexford Capital West Palm Beach, Florida $690M AUM 57.92% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
NCNMGF
Nano-Cap New Millennium Growth Fund Staten Island, New York $107M AUM
SAM
Silvercrest Asset Management New York $13.8B AUM 28.39% 1-Year Est. Return
KCM
Kennedy Capital Management St Louis, Missouri $4.72B AUM 36.69% 1-Year Est. Return
FCM
FourWorld Capital Management New York $196M AUM 42.39% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
MBAM
Mink Brook Asset Management West Palm Beach, Florida $179M AUM 37.68% 1-Year Est. Return

Ameriprise's XGN Position: Q1 2026 in Review

Ameriprise sold out of Exagen (XGN) in Q1 2026, closing a stake of 192,419 shares — an estimated $1.17M sold.

Ameriprise first reported a position in XGN in Q2 2025 and held it in 3 quarters. The position peaked at $1.41M in Q3 2025. 61 funds tracked by Wall St. Rank hold XGN as of Q1 2026.

  • Ameriprise reported no remaining Exagen position as of Q1 2026 after selling out during the quarter.
  • Ameriprise sold 192,419 Exagen shares in Q1 2026, an estimated $1.17M.
  • Ameriprise first reported a position in Exagen in Q2 2025 and held it in 3 quarters.
  • Ameriprise's Exagen position peaked at $1.41M in Q3 2025.
  • 61 funds tracked by Wall St. Rank held Exagen as of Q1 2026.

Based on Ameriprise's 13F filing for Q1 2026, filed 15 May 2026.